2010, Number 3
<< Back Next >>
Rev Endocrinol Nutr 2010; 18 (3)
Prevalence of primary aldosteronism among hypertensive patients from Centro Médico Nacional «20 de Noviembre»
Joya-Galeana JG, Yánez-Jácome JC, Martínez-Elizondo G, Juárez-Rico MS, Stempa-Blumenfeld O, Escudero-Licona I
Language: Spanish
References: 20
Page: 135-140
PDF size: 305.53 Kb.
ABSTRACT
Background: Systemic hypertension is one of the main health problems in Mexico. It was believed that the endocrine causes of hypertension constitute only 1%. However, since 1994 findings in epidemiologic studies have shown a prevalence of primary aldosteronism as high as 13%.
Objective: This study was designed to determinate the prevalence of this pathology in the mexican population.
Material and methods: 40 hypertensive patients were recruited. All the patients were older than 18 years, and those patients referred for secondary hypertension evaluation were excluded. Plasma aldosterone concentration, plasma renin activity and the ratio of these two hormones were determinated. When the ratio was greater than 20, an aldosterone suppression test with an oral sodium load was performed in order to confirm the diagnosis of primary aldosteronism. In those patients with biochemical diagnosis, an adrenal computed tomography was performed.
Results: The screening test was positive in 42.5% of the population yet, primary aldosteronism was documented in only 3 patients. Bilateral idiopathic hyperplasia was confirmed as the etiology in 2 of these subjects.
Conclusions: The prevalence of primary aldosteronism in this population of hypertensive mexican subjects was 7.5 %.
REFERENCES
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones PW, Materson BJ, Oparil S, Wright JT. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2571.rafía computada.
Velázquez MO, Rosas PM, Lara EA, Pastelín HG. Hipertensión arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002; 72: 71-84.
Conn JW. Primary aldosteronism: A new clinical syndrome. J Clin Lab Med 1955; 45: 6-17.
Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 1981; 141: 1589-1593.
Young WF. Primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208- 2213.
Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318.
Kumar A, Lall SB, Ammini A, Peshin SS, Karmarkar MG, Talwar KK, Seth SD. Screening of a population of young hypertensives for primary hyperaldosteronism. J Hum Hypertens 1994; 8: 731-732.
Lim P, Dow E, Brennan G, Jung R, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-315.
Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
Fardella C, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007; 30: 1699-1703.
Calhoun D, Nishizaka MA, Zaman MA, Thakkar RB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2004; 40: 892- 896.
O`Rorke, Jane E. Richardson Scott. What to do when blood pressure is difficult to control? BMJ 2003; 322: 1229-1232.
Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-618.
Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Jean- Jacques M. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. JACC 2005; 45: 1243-1248.
Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353: 1341-1347.
Seirfarth S, Trenkelt H, Shobel E, Hahn EG, Hensen J. Influence of antihypertensive medication in the differential diagnosis of essential hypertension and primary aldosteronism. Clinical Endocrinology 2002; 57: 465-547.
Yáñez-Jácome JC, Vergara-López A, Joya-Galeana J, Juárez- Rico MS, Martínez-Elizondo G. Valor del índice aldosterona plasmática/actividad de renina plasmática (IAR) en individuos sanos del CMN «20 de Noviembre». Rev Endocrinol Nutr 2009; 17: 148-152.
Seiler L, Rump L, Schulte-Monting J, Slawik M, Born K, Pavenstädt H et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329-337.
Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.